Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renoprotection. We determined whether canagliflozin decreases albuminuria and reduces renal function decline independently of its glycemic effects in a secondary analysis of a clinical trial in 1450 patients with type 2 diabetes receiving metformin and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6–8 mg. End points were annual change in eGFR and albuminuria over 2 years of follow-up. Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3 ml/min per 1.73 m 2 per year (95% confidence interval [95% CI], 2.8 to 3.8), 0.5 ml/min per 1.73 m 2 per year (95% CI, 0.0 to 1.0), and 0.9 ml/min per 1.73 m 2 per year (95% CI, 0.4 to 1.4), respectively ( P <0.01 for each canagliflozin group versus glimepiride). In the subgroup of patients with baseline urinary albumin-to-creatinine ratio ≥30 mg/g, urinary albumin-to-creatinine ratio decreased more with canagliflozin 100 mg (31.7%; 95% CI, 8.6% to 48.9%; P =0.01) or canagliflozin 300 mg (49.3%; 95% CI, 31.9% to 62.2%; P <0.001) than with glimepiride. Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c of 0.81%, 0.82%, and 0.93%, respectively, at 1 year and 0.55%, 0.65%, and 0.74%, respectively, at 2 years. In conclusion, canagliflozin 100 or 300 mg/d, compared with glimepiride, slowed the progression of renal disease over 2 years in patients with type 2 diabetes, and canagliflozin may confer renoprotective effects independently of its glycemic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, SGLT2 inhibitors reduce kidney tubular glucose reabsorption, weight, systemic blood pressure, intraglomerular pressure, and albuminuria and slow GFR loss through mechanisms that appear independent of glycemia (31,(97)(98)(99)(100)(101).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [98]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Research works printed but not linked: 1
- 2015, Standards of medical care in diabetes–2015., Diabetes Care, 38, S1
Cited by
Items 101–200 of 360
Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
“In a study of 1450 T2DM patients on metformin randomly assigned to either canafliglozin or glimepiride, canagliflozintreated patients had significantly less decline in estimated glomerular filtration rate and greater reduction in urinary albumin-to-creatinine ratio compared to glimeperide [107].”
BackgroundSGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
Piperidou, A., Loutradis, C., & Sarafidis, P. A. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00393-4 · Cited by 51
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Škrabić, R., Kumrić, M., Vrdoljak, J., Rušić, D., Skrabic, I., Vilović, M., Martinović, D., Duplancic, V., Kurir, T. T., & Božić, J. (2022) · Biomedicines · doi:10.3390/biomedicines10102458 · Cited by 60
CHILTON, R. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13854 · Cited by 55
“with SGLT-2is may contribute to reductions in intraglomerular pressure.(98) These alterations in renal haemodynamics with SGLT-2is present clinically as short-term reductions in albuminuria and eGFR, with subsequent stabilization of eGFR with long-term SGLT-2i therapy.”
BackgroundShould Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Canagliflozin review – safety and efficacy profile in patients with T2DM
Jakher, H., Chang, T. I., Tan, M., & Mahaffey, K. W. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s184437 · Cited by 48
“01 for each canagliflozin group compared to glimepiride).(16) In the CANVAS integrated analyses, composite outcome of sustained reduction of eGFR, the need for renal replacement therapy, and death from renal causes occurred less frequently in patients assigned canagliflozin compared with placebo”
An, X., Liao, G., Chen, Y., Luo, A., Liu, J., Yuan, Y., Li, L., Yang, L., Wang, H., Liu, F., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1401-z · Cited by 50
Xie, Y., Bowe, B., Gibson, A. K., McGill, J. B., Maddukuri, G., & Al-Aly, Z. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2488 · Cited by 48
Xie, Y., Bowe, B., Gibson, A. K., McGill, J. B., Maddukuri, G., & Al‐Aly, Z. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020237 · Cited by 45
SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
Podestà, M. A., Sabiu, G., Galassi, A., Ciceri, P., & Cozzolino, M. G. (2023) · Biomedicines · doi:10.3390/biomedicines11020279 · Cited by 65
“However, the protective effects of SGLT2is on the kidney appear to be independent of their effects on blood sugar levels [16], and have been predominantly ascribed to modifications in renal hemodynamics.”
BackgroundLoffler, K. A., Heeley, E., Freed, R., Anderson, C. S., Brockway, B., Corbett, A., Chang, C. L., Douglas, J. A., Ferrier, K., Graham, N., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201703-0603oc · Cited by 46
“Diabetes, n (%) 22 (22) 26 (27) ESS score >11, n (%) 32 (31) 23 (23) Blood pressure–lowering drugs, n (%) 96 (94) 88 (90) ACE inhibitor/ARB, n (%) 72 (71) 71 (72) Lipid-modifying agents, n (%) 94 (92) 89 (91) Insulin, n (%) 5 (5) 7 (7) Oral antidiabetic agents, n (%) 15 (15) 22 (22) Antiplatelet/antithrombotic agents,…”
BackgroundSGLT2 inhibitors and the kidney: Effects and mechanisms
Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. S. (2018) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.06.003 · Cited by 46
Liu, H., Sridhar, V. S., Lovblom, L. E., Lytvyn, Y., Burger, D. E., Burns, K. D., Brinc, D., Lawler, P. R., & Cherney, D. Z. I. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.022 · Cited by 47
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.12.010 · Cited by 47
“In a recent secondary analysis of a large clinical trial of 1450 patients with T2D treated with metformin and randomly assigned to receive once daily either canagliflozin (100 mg or 300 mg) or glimepiride, a sulphonylurea used as a glucoselowering active reference, the objective was to determine whether the SGLT2 inhi…”
BackgroundResultInfluentialVanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 49
“Also in a post hoc analysis of a comparison with glimepiride, a nephroprotective effect was described for canagliflozin [277].”
ResultThe Role of SGLT2 Inhibitors in Vascular Aging
Liu, L., Ni, Y., Zhan, J., & Liu, Y. (2021) · Aging and Disease · doi:10.14336/ad.2020.1229 · Cited by 50
“Meanwhile, a clinical study established that Canagliflozin 100 or 300 mg/d could delay the progression of kidney diseases in patients with T2DM for more than 2 years compared with glimepiride [93].”
BackgroundCherney, D. Z. I., Heerspink, H. J. L., Frederich, R., Maldonado, M., Liu, J., Pong, A., Xu, Z. J., Patel, S., Hickman, A., Mancuso, J. P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05133-4 · Cited by 43
Self-citationCooper, M. E., Inzucchi, S. E., Zinman, B., Hantel, S., von Eynatten, M., Wanner, C., & Koitka‐Weber, A. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.03.432 · Cited by 44
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 61
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 57
Management of diabetes mellitus in chronic kidney disease
Garla, V. V., Kanduri, S. R., Yanes-Cardozo, L. L., & Lien, L. F. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03015-3 · Cited by 46
Xie, Y., Bowe, B., Gibson, A. K., McGill, J. B., Yan, Y., Maddukuri, G., & Al-Aly, Z. (2020) · Diabetes Care · doi:10.2337/dc20-1231 · Cited by 40
“that also suggests a glucose-independent mechanism likely involving reduced glomerular hyperfiltration, which may also explain the acute early reduction in eGFR in the SGLT2i group, which then stabilized to yield less annual reduction in eGFR (eGFR preservation) compared with the control arm (13,45,46).”
ResultCardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
“Heerspink et al.(69) have demonstrated that canagliflozin reduced GFR decline and albumin: creatinine ratio in diabetic patients, independent of SGLT-2 glycaemic effects.”
Small Fiber Neuropathy in Diabetes Polyneuropathy: Is It Time to Change?
Sharma, S., Vas, P. R. J., & Rayman, G. A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821996434 · Cited by 44
Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects
Satirapoj, B. (2017) · Kidney Diseases · doi:10.1159/000471765 · Cited by 42
Rajasekeran, H., Cherney, D. Z., & Lovshin, J. A. (2017) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000343 · Cited by 37
Cao, H., Rao, X., Jia, J., Yan, T., & Li, D. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01989-7 · Cited by 44
“The investigators have obtained confirmation with the large-scale trial that the renal protective effect of SGLT2 inhibitors is independent of its hypoglycemic effect [25].”
BackgroundWilliams, J. K. Y. (2017) · Nursing Clinics of North America · doi:10.1016/j.cnur.2017.07.007 · Cited by 40
Satirapoj, B., Korkiatpitak, P., & Supasyndh, O. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy122 · Cited by 37
Kinguchi, S., Wakui, H., Ito, Y., Kondo, Y., Azushima, K., Osada, U. N., Yamakawa, T., Iwamoto, T., Yutoh, J., Misumi, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0912-3 · Cited by 39
Khoo, C. M., Deerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Mithal, A., Luk, A. O. Y., Suastika, K., Yoon, K., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14251 · Cited by 41
“A secondary analysis of the Canagliflozin Treatment and Trial Analysis versus Sulphonylurea (CANTATA-SU) study evaluated the renal effects of canagliflozin (100 and 300 mg) compared with glimepiride (uptitrated to 6-8 mg) in T2D patients on metformin (N = 1450).(84) Over the 2 years of follow-up, eGFR decline was slow…”
MethodResultSGLT2 inhibition to address the unmet needs in diabetic nephropathy
Barutta, F., Bernardi, S., Gargiulo, G., Durazzo, M., & Gruden, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3171 · Cited by 48
“Canagliflozin slowed progression of renal function decline compared with glimepiride in the CANTATA‐SU study despite similar HbA1c levels in the two arms of the study.(46) Moreover, adjustment for changes in these variables did not modify the results on various renal end‐points,(34,36,37) making unlikely the possibili…”
ResultSodium-glucose cotransporter inhibitors: beyond glycaemic control
Vergara, A., Jacobs-Cachá, C., & Soler, M. J. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz019 · Cited by 41
“[11] demonstrated that canagliflozin slowed renal disease”
Dandona, P., & Chaudhuri, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12937 · Cited by 35
SGLT2 inhibitors – a potential treatment for Alport syndrome
Mabillard, H. R., & Sayer, J. A. (2020) · Clinical Science · doi:10.1042/cs20191276 · Cited by 38
Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Pecoits-Filho, R., & Perkovic, V. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07680717 · Cited by 33
“Finally, SGLT2i has been shown to slow the progression of kidney function decline independently of glycemic effects (6).”
BackgroundSelf-citationKuriyama, S. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000501081 · Cited by 37
Kanie, T., Mizuno, A., Yoneoka, D., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., & Kwong, J. S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650 · Cited by 34
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 70
Cao, H., Liu, T., Wang, L., & Ji, Q. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14702 · Cited by 34
“While this may result in an acute decrease in eGFR levels, eGFR stability is seen in the long run, leading to a nephroprotective effect.(31)”
BackgroundRenal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 54
The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update
Yaribeygi, H., Simental‐Mendía, L. E., Banach, M., Bo, S., & Sahebkar, A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109526 · Cited by 33
Akiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111984 · Cited by 32
“This idea was tested in a secondary analysis of clinical trials in which canagliflozin was compared with glimepiride (52).”
MethodEffect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy
Dong, Y., Shi, S., Liu, L., Zhou, X., Lv, J., & Zhang, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1242241 · Cited by 36
Xu, J., Kitada, M., & Koya, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165756 · Cited by 32
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Kleinaki, Z., Kapnisi, S., Theodorelou‐Charitou, S., Nikas, I. P., & Paschou, S. Α. (2020) · HORMONES · doi:10.1007/s42000-020-00212-y · Cited by 32
Desai, M. G., Yavin, Y., Balis, D. A., Sun, D., Xie, J., Canovatchel, W. J., & Rosenthal, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12876 · Cited by 27
“These results are consistent with an analysis of renal-related AEs with canagliflozin in a pooled population from four 26-week, placebo-controlled studies12 and with results from the EMPA-REG OUTCOME study of the SGLT2 inhibitor in patients with T2DM and established cardiovascular disease, where an increased incidence…”
BackgroundSelf-citationCardiovascular benefits of the newer medications for treating type 2 diabetes mellitus
Yandrapalli, S., & Aronow, W. S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.70 · Cited by 30
“This study was not designed nor powered to compare the renoprotective effects of canagliflozin versus glimepiride, so the results should be interpreted as hypothesis-generating (47).”
BackgroundResultInfluentialCardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
“reductions in albuminuria and eGFR, followed by longer term eGFR stability.(85) However, it should be noted that the”
Roy, A., Maiti, A., Sinha, A., Baidya, A., Basu, A. K., Sarkar, D., Sanyal, D., Biswas, D., Maisnam, I., Pandit, K., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00921-y · Cited by 27
Lin, B., Ma, Y., & Jun-wei, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.870049 · Cited by 29
“Dipeptidylpeptidase-4 inhibitors and Glucagon-like peptide-1 receptor agonists, in particular, prevent albuminuria progression, while sodium-glucose cotransporter-2 inhibitors diminish renal disease progression and lessen the demand for kidney replacement therapy (Wanner et al., 2016; Groop et al., 2017; Heerspink et…”
BackgroundThe Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe, Y., & Vallon, V. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020032 · Cited by 34
Chen, X., Wang, J., Lin, Y., Liu, Y., & Zhou, T. (2022) · Cells · doi:10.3390/cells11233913 · Cited by 29
The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes
Jaikumkao, K., Pongchaidecha, A., Chatsudthipong, V., Chattipakorn, S. C., Chattipakorn, N., & Lungkaphin, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.095 · Cited by 28
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Budoff, M. J., & Wilding, J. P. H. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12948 · Cited by 30
Arora, N., Katz, R., & Bansal, N. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2019.12.007 · Cited by 30
Chan, Y., Chen, S., Chao, T., Kao, Y., Huang, C., & Chu, P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14446 · Cited by 26
“Chronic kidney disease 758 (17) 727 (20) 465 (20) 226 (23) 90 (21) <.”
Afşar, B., & Afşar, R. E. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00442-4 · Cited by 32
“Indeed, studies showed that the beneficial effects of SGLT2i were independent of blood glucose reduction and HbA1c [5, 6].”
BackgroundKalra, S., Ghosh, S. K., Aamir, A., Ahmed, M. T., Amin, M. F., Bajaj, S., Baruah, M., Bulugahapitiya, U., Das, A., Giri, M., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196029 · Cited by 31
“[58] Canagliflozin has demonstrated an improvement in urinary albumin‐creatinine ratio and eGFR as compared with glimepiride over the period of 2 years, thus slowing the renal disease and providing reno‐protective effects independent of its glycemic effect.[59] Dapagliflozin, on the other hand, has been studied only i…”
The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Loutradis, C., Papadopoulou, E., Angeloudi, E., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191029111713 · Cited by 25
Neuen, B. L., Jardine, M., & Perkovic, V. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz252 · Cited by 28
“This is further supported by head-to-head data showing that canagliflozin slows the loss of kidney function compared with glimepiride [19] and that kidney benefits are independent of HbA1c before and during therapy, and by the degree of HbA1c lowering [20].”
BackgroundSelf-citationRenoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 33
Osonoi, T., Gouda, M., Kubo, M., Arakawa, K., Hashimoto, T., & Abe, M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0169 · Cited by 26
“Previous investigations on SGLT2 inhibitors, including canagliflozin, putatively by activated tubuloglomerular feedback,(37) showed an acute decline in eGFR followed by a period of maintained kidney function.(20,29,38,39) A similar reduction in eGFR was reported with renin–angiotensin–aldosterone system inhibitors, an…”
BackgroundResultInfluentialChen, L., Cheng, H. T., Liao, C.-K., Kuan, Y., Liang, T.-J., Tseng, T.-J., & Lin, H.-C. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105461 · Cited by 29
Sex-Related Aspects in Diabetic Kidney Disease—An Update
Loeffler, I., & Ziller, N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082834 · Cited by 27
Heerspink, H. J. L., Sjöström, C. D., Inzucchi, S. E., Hallow, K. M., Cain, V. A., Rossing, P. R., Stefánsson, B. V., & Sartipy, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13579 · Cited by 27
“The similarity in changes in HbA1c, body weight and hematocrit between the two groups is in accordance with previous studies.(5,19,20) The larger and sustained reduction in eGFR in the responder population is interesting and is most probably of haemodynamic origin because SGLT2 inhibitors acutely decrease renal blood…”
ResultSelf-citationRecent advances in new-onset diabetes mellitus after kidney transplantation
Montada-Atin, T., & Prasad, G. V. R. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.541 · Cited by 24
Park, J., Shin, D. W., Han, K., Kim, D., Chun, S., & Jang, H. R. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab140 · Cited by 28
Tian, L., Cai, Y., Zheng, H., Ai, S., Zhou, M., Luo, Q., Tang, J., Liu, W., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.691878 · Cited by 23
Hisadome, Y., Mei, T., Noguchi, H., Ohkuma, T., Sato, Y., Kaku, K., Okabe, Y., & Nakamura, M. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001228 · Cited by 26
Tauber, P., Sinha, F., Berger, R. S., Gronwald, W., Dettmer, K., Kühn, M., Trum, M., Maier, L. S., Wagner, S., & Schweda, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.761855 · Cited by 31
“For example, post hoc analyses of clinical trials revealed that renal protection by empagliflozin (EMPA) and canagliflozin was independent of HbA1C levels (glycated hemoglobin) before and during therapy with SGLT2 inhibitors (Heerspink et al., 2017; Cooper et al., 2019).”
Lyu, Y., Zhang, Y., Yang, M., Lin, L., Yang, X., Cheung, S. C. K., Shaw, P. C., Chan, P. K. S., Kong, A. P. S., & Zuo, Z. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116818 · Cited by 23
Bystad, E. W., Stefansson, V. T. N., Eriksen, B. O., & Melsom, T. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.06.022 · Cited by 26
“C KD affects more than 10% of the populationglobally and has become one of the leading causes of mortality worldwide.1 Hypertension, hyperglycemia, and obesity are important risk factors for CKD.2 These metabolic abnormalities are often clustered together in MetS.3 MetS is a risk factor for diabetes, cardiovascular di…”
BackgroundResultInfluentialNusca, A., Piccirillo, F., Viscusi, M. M., Giannone, S., Mangiacapra, F., Melfi, R., Ricottini, E., Ussia, G. P., & Grigioni, F. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001329 · Cited by 25
Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258055 · Cited by 24
“These beneficial effects were independent of the effect of the drug on glycemic control[79].”
BackgroundShirakabe, A., Matsushita, M., Kiuchi, K., Okazaki, H., Inami, T., Takayasu, T., Asano, M., Nomura, A., Kobayashi, N., Okajima, F., et al. (2020) · Circulation Reports · doi:10.1253/circrep.cr-20-0041 · Cited by 22
Challenging 2019 ESC guidelines for the management of type 2 diabetes
Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.006 · Cited by 20
Tanaka, M., Yamakage, H., Inoue, T., Odori, S., Kusakabe, T., Shimatsu, A., & Satoh‐Asahara, N. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3473-19 · Cited by 24
“In other intervention studies, improvements in the eGFR and UACR with SGLT2 inhibitors in patients with type 2 diabetes have also been reported (20-22).”
BackgroundClosing the gap between evidence and practice in chronic kidney disease
Jardine, M., Kasiske, B. L., Adu, D., Alrukhaimi, M. N., Ashuntantang, G., Basnet, S., Chailimpamontree, W., Craig, J. C., O'Donoghue, D. J., Perkovic, V., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.006 · Cited by 26
Self-citationFeng, C., Minxiang, W., Chen, Z., Yu, X., Nie, Z., Zhao, Y. C., & Bao, B. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02112-6 · Cited by 22
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?
de Boer, I. H., & Kahn, S. E. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060650 · Cited by 19
Loutradis, C., Papadopoulou, E., Theodorakopoulou, M. P., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0514 · Cited by 23
Efficacy of dotinurad in patients with severe renal dysfunction
Kurihara, O., Yamada, T., Kato, K., & Miyauchi, Y. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02419-w · Cited by 21
Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity
Saly, D. L., & Perazella, M. A. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00250.2017 · Cited by 18
Kuriyama, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1673-0 · Cited by 17
Davazdahemami, B., & Delen, D. (2019) · Expert Systems with Applications · doi:10.1016/j.eswa.2019.01.006 · Cited by 18
Tanaka, A., Shimabukuro, M., Okada, Y., Sugimoto, K., Kurozumi, A., Torimoto, K., Hirai, H., Node, K., & the PROCEED trial investigators (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01065-w · Cited by 20
Cersósimo, E., & Miles, J. M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180813124645 · Cited by 18
Narrative review of the effects of antidiabetic drugs on albuminuria
Yaribeygi, H., Atkin, S. L., Katsiki, N., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27503 · Cited by 17
Luo, Y. L., Lü, K., Liu, G., Wang, J., Laurent, I., & Zhou, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0707-4 · Cited by 18
Olufade, T. O., Jiang, L., Israni, R., Huang, J., & Gosmanov, A. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14530 · Cited by 17
Manski-Nankervis, J.-A. E., Thuraisingam, S., Sluggett, J. K., Lau, P. M.-Y., Blackberry, I., Ilomäki, J., Furler, J., & Bell, J. S. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.09.001 · Cited by 15
Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
Heerspink, H. J. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz033 · Cited by 17
“Furthermore, active controlled studies have shown that at equal glycaemic control, eGFR decline was significantly less in SGLT2 inhibitor-treated compared with control-treated patients [12].”
ResultSelf-citationTziastoudi, M., Pissas, G., Golfinopoulos, S., Filippidis, G., Dousdampanis, P., Eleftheriadis, T., & Stefanidis, I. (2023) · Life · doi:10.3390/life13122338 · Cited by 21
Zhang, Y., Luo, J., Li, B., Xu, J., Yu, H., & Chen, N. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03833-2 · Cited by 19
“These beneficial effects seem to be independent of their hypoglycemic effects [14–16].”
BackgroundKobayashi, K., Toyoda, M., Kimura, M., Hatori, N., Furuki, T., Sakai, H., Takihata, M., Umezono, T., Ito, S., Suzuki, D., et al. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118802759 · Cited by 14
der Beek, A. B. V. D. A., Koomen, J. V., Dekkers, C. C. J., Barbour, S. J., Boulton, D. W., Gansevoort, R. T., Greasley, P. J., Gafor, A. H. A., Laverman, G. D., Li, Q., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00956-1 · Cited by 17
Self-citationChábová, V. Č., & Zakiyanov, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052812 · Cited by 18
“In fact, hemodynamic, glomerular and tubulointerstitial mechanisms work in concert and all of them contribute to the beneficial effect, demonstrated as a slower deterioration in glomerular filtration [94], and better renal survival in clinical studies, together with decreased albuminuria [3,95].”
BackgroundWoodhams, L., Chalmers, L., Sim, T. F., Yeap, B. B., Schlaich, M. P., Schultz, C. J., & Hillis, G. S. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108456 · Cited by 17
Metadata
- Authors
- Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V.
- Affiliations
- University Medical Center Groningen (NL)
- Janssen Research & Development (United States) (US)
- The University of Sydney (AU)
- Corresponding author
- Heerspink, Hiddo J. L.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-08-18
- Volume
- 28
- Issue
- 1
- Pages
- 368-375
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC5198289
- OpenAlex
- W2512006388
- Cited by
- 361
- References
- 22
- Citations by year
- 2026: 30 · 2025: 14 · 2024: 17 · 2023: 28 · 2022: 28 · 2021: 44 · 2020: 41 · 2019: 49 · 2018: 49 · 2017: 51 · 2016: 10
- FWCI
- 53.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, renal function decline, EGFR, albuminuria, glimepiride, metformin, renal protection, glycemic control, albumin-creatinine ratio, dose-response relationship, diabetic nephropathy, secondary prevention, cardiovascular risk reduction, HbA1c
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Sulfonylurea Compounds, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.